MedTrace Logo

Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation

NCT01557075 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2012-03-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether high dose statin therapy in patients with aspirin mono antiplatelet therapy who had received drug-eluting stent (DES) previously and were free of the adverse cardiac events during the first 12 months could be superior over pravastatin therapy in the prevention of late adverse cardiac and cerebrovascular events during the additional 12 months.

Study Design.

Conditions

  • Drug-eluting Stent (DES)

Interventions

DRUG

Atorvastatin (High dose statin treatment)

Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program * Atorvastatin 40 mg daily for 12 months after randomization

DRUG

Pravastatin (High dose statin treatment)

Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program Pravastatin 20mg daily for 12 months after randomization

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Myeong-Ki Hong, MD.PhD. · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01557075 on ClinicalTrials.gov